Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Pragmatiston Feb 10, 2021 1:05am
332 Views
Post# 32521791

H2s Covid

H2s Covid
https://journals.lww.com/shockjournal/Fulltext/2020/11000/Serum_Hydrogen_Sulfide_and_Outcome_Association_in.8.aspx
 
This is one of the few published studies (maybe the only one?) where the researchers evaluated H2S directly against covid. 
 
The researchers measured serum H2S in 74 hospitalized patients with covid pneumonia. They found that survivors had significantly higher H2S levels on days 1 and 7 after admission. And that patients who had sustained elevated H2S levels after 7 days "...had no risk of an unfavorable outcome."  Quite a bold statement for a small trial!
 
This once again shows that H2S donation might be a possible treatment for Covid-related pneumonia. Perhaps more so if it is combined with an anti-inflammatory drug?

I understand that a slow H2S release rate is critical and that perhaps Oten doesn't  meet this requirement. However, if we have a chemist onboard who specializes in developing tunable release rates....well...anything is possible. 

Just a thought.
<< Previous
Bullboard Posts
Next >>